Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation.

MLA

Shelly, Shahar, et al. “Cancer and Immune-Mediated Necrotizing Myopathy: A Longitudinal Referral Case-Controlled Outcomes Evaluation.” Rheumatology, vol. 62, no. 1, Jan. 2023, pp. 281–89. EBSCOhost, https://doi.org/10.1093/rheumatology/keac144.

APA

Shelly, S., Beecher, G., Milone, M., Liewluck, T., Ernste, F., Triplett, J., Naddaf, E., Zekeridou, A., McKeon, A., Pittock, S. J., Dubey, D., Mills, J. R., Mandrekar, J., & Klein, C. J. (2023). Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology, 62(1), 281–289. https://doi.org/10.1093/rheumatology/keac144

Chicago

Shelly, Shahar, Grayson Beecher, Margherita Milone, Teerin Liewluck, Floranne Ernste, James Triplett, Elie Naddaf, et al. 2023. “Cancer and Immune-Mediated Necrotizing Myopathy: A Longitudinal Referral Case-Controlled Outcomes Evaluation.” Rheumatology 62 (1): 281–89. doi:10.1093/rheumatology/keac144.